Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Australia's Immuron soars on positive trial results for gastric drug

** Shares of Immuron  IMC.AX  rise as much as 104.6% to
A$0.135, posting their biggest intraday gain since July 21, 2020
    ** Stock hits its highest level since Feb 8, 2022
    ** Drugmaker says reports positive results from the clinical
trials for its flagship diarhhea drug, Travelan
    ** Says results support Travelan's progress to late-stage
clinical trials in the U.S.
    ** Adds co is proceeding to Phase 3 trial registration
strategy with U.S. FDA
    ** About 19.7 mln shares change hands, compared with the
30-day average volume of 111,932
    ** Stock down 14.3% YTD as of last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))

Recent news on Immuron

See all news